MSB Trading 2020 - a new dawn, page-2971

Abundance of Opportunity50 minutes ago

My post from 28 days ago. I tried to tell you.

I bet accordingly...

“Here’s how I see the interim analysis in ARDS going down:

The speed of enrollment lends itself to a majority of the 90 patients being in the moderate ARDS category (<200 mmHg). This means less mortality in the placebo group. There will be a decreased mortality rate using the cells vs. placebo, but it will not be statistically significant. In severe ARDS (<100 mmHg), you will see a more significant difference vs. placebo. However, due to the low number of severe patients enrolled, it will also not be statistically significant. I expect the trial to be able to continue to the next interim readout at 135 patients, or 45%.”

The new issue might be that there are even fewer incidences of severe ARDS going forward with the use of Remdesivir, steroids, and others treatments. Hopefully, MESO didn’t put all their eggs in this basket. Better to focus on ARDS from a multitude of causes like $ATHX and Healios have done.